A group of imidazopyrimidine ligands of benzodiazepine receptors has been shown to produce anti-conflict effects in a punished rat operant task, at comparable doses to classical benzodiazepine agonists such as diazepam. Most were able to attenuate the convulsant effects of pentylenetetrazole and ele
Animal pharmacokinetics of selected imidazopyrimidine ligands for benzodiazepine receptors
โ Scribed by Ian R. Ager; Anne B. Doyle; Peter W. Hairsine; Keith P. McDonald; Dr. Peter Miller; Fred L. Parker
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 687 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0272-4391
No coin nor oath required. For personal study only.
โฆ Synopsis
The kinetics of imidazopyrimidines selected for development were investigated in the rat, dog, and cynomolgus monkey using high pressure liquid chromatography (HPLC) measurements of levels. These data were compared with levels estimated by benzodiazepine radioreceptor binding assays and with the in vivo binding of the compounds to these receptors in the brain. RU 32698, RU 33203, and RU 33543 were found in relatively high peak levels in the plasma of rats (1-6 kg/ml at 10 min-1 hr after 10-100 mg/kg orally [P.o.]), dogs (4-12 pg/ml at 2 hr after 20 mglkg P.o.), and monkeys (0.4-10 pg/ml after 150-500 mg/kg p.0.). HPLC analysis showed one further prominent peak for either RU 33203 or RU 33543 which had similar characteristics in all three species and may represent a common route of metabolism. In the rat these putative metabolites were at low levels in the brain when compared with parent levels. Nuclear magnetic resonance (NMR) and mass spectra of these isolated metabolites identified them as the hydroxymethyl derivatives on the oxadiazole ring. The synthesised metabolites showed two to six times less affinity for 3H-flunitrazepam-labelled benzodiazepine receptors, and the RU 33203 metabolite, RU 341 49, did not displace in vivo benzodiazepine receptor binding after administration to mice, despite high plasma levels. This, coupled with little activity in several in vivo pharmacological models, suggests that this metabolite only poorly crosses the blood brain barrier. A pharmacological effect in the stress-induced ultrasounds model is consistent with this view as the rat pups used have a poor blood brain barrier. Daily dosing of low, pharmacologically
๐ SIMILAR VOLUMES
A nonisotopic receptor assay using the biotin-1012-S conjugate was developed and the usefulness of this conjugate as a probe ligand for the benzodiazepine receptor was evaluated. The conjugate was incubated in a receptor suspension, and then the concentration of free conjugate in the supernatant was